GRM5 and fragile X syndrome: Thus, despite the preclinical evidence in the FXS mouse model supporting the efficacy of negative allosteric modulators targeting mGluR5, the mechanism proposed by the “mGluR theory” did not translate into observable benefits for individuals with FXS.